Joel Beatty analyst BAIRD

Currently out of the existing stock ratings of Joel Beatty, 197 are a BUY (72.96%), 61 are a HOLD (22.59%), 12 are a SELL (4.44%).

Joel Beatty

Work Performance Price Targets & Ratings Chart

Analyst Joel Beatty works at BAIRD with a stock forecast success ratio of 51.15% fulfilled within 207.51 days on average. Previously, Joel Beatty worked at CITI.

Joel Beatty’s has documented 536 price targets and ratings displayed on 54 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BMRN, Biomarin Pharmaceutical at 30-Jan-2024.

Wall Street Analyst Joel Beatty

Analyst best performing recommendations are on LIFE (ATYR PHARMA).
The best stock recommendation documented was for LIFE (ATYR PHARMA) at 5/14/2018. The price target of $14 was fulfilled within 2 days with a profit of $7.7 (35.48%) receiving and performance score of 177.42.

Average potential price target upside

ALNY Alnylam Pharmaceuticals AMRN Amarin PLC ARCT Arcturus Therapeutics Holdings ARNA Arena Pharmaceuticals BPMC Blueprint Medicines Corp CBAY Cymabay Therapeu DBVT DBV Technologies EIDX Eidos Therapeutics ESPR Esperion Therapeutics FGEN FibroGen HALO Halozyme Therapeutics IGMS IGM Biosciences IONS Ionis Pharmaceuticals MDCO The Medicines Company MDGL Madrigal Pharmaceuticals MIRM Mirum Pharmaceuticals NGM NGM Biopharmaceuticals NK NantKwest NVAX Novavax PHAS PhaseBio Pharmaceuticals PTCT PTC Therapeutics SLDB Solid Biosciences LLC SNDX Syndax Pharmaceuticals SRPT Sarepta Therapeutics VIR Vir Biotechnology VNDA Vanda Pharmaceuticals ARGX argenx NV ADR ARWR Arrowhead Pharmaceuticals CATB Catabasis Pharmaceuticals CRDF Cardiff Oncology EDIT Editas Medicine ICPT Intercept Pharmaceuticals NRIX Nurix Therapeutics  BCEL Atreca TCON TRACON Pharmaceuticals GERN Geron KURA Kura Oncology NERV Minerva Neurosciences AMAM Ambrx Biopharma . American Depositary Shares XFOR X4 Pharmaceuticals IDYA Ideaya Biosciences ATXS Astria Therapeutics BYSI BeyondSpring CDTX Cidara Therapeutics ELOX Eloxx Pharmaceuticals INO Inovio Pharmaceuticals LIFE aTyr Pharma MLND Millendo Therapeutics PLRX Pliant Therapeutics  RARE Ultragenyx BMRN Biomarin Pharmaceutical LPTX Leap Therapeutics IBRX Immunitybio IMMP Immutep Ltd ADR

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

225

$54.97 (32.33%)

225

2 days ago

2/7 (28.57%)

$54.97 (32.33%)

435

Buy

235

$64.97 (38.21%)

235

2 days ago

2/15 (13.33%)

$64.97 (38.21%)

149

Buy

173

$2.97 (1.75%)

173

2 days ago

3/8 (37.5%)

$2.97 (1.75%)

27

Hold

176

$5.97 (3.51%)

176

8 days ago

5/7 (71.43%)

$5.97 (3.51%)

36

Buy

200

$29.97 (17.63%)

200

8 days ago

4/10 (40%)

$29.97 (17.63%)

139

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Joel Beatty is most bullish on?

Potential upside of $19.12 has been obtained for RARE (ULTRAGENYX)

Which stock is Joel Beatty is most reserved on?

Potential downside of $0.3 has been obtained for AMAM (AMBRX BIOPHARMA . AMERICAN DEPOSITARY SHARES)

What Year was the first public recommendation made by Joel Beatty?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?